Biventricular Epicardial...
Financiado
A revolutionary technology platform for providing life-saving treatment for end-...
A revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
Over 500K patients in the EU and US suffer from end-stage heart failure (HF), with a life expectancy of <1 year in 38% of cases. The prevalence of HF has increased recently, mainly due to improved survival after heart attacks. Suc...
Over 500K patients in the EU and US suffer from end-stage heart failure (HF), with a life expectancy of <1 year in 38% of cases. The prevalence of HF has increased recently, mainly due to improved survival after heart attacks. Such patients require mechanical support of their hearts. Available treatment options are heart transplantation (HTX) and ventricular assist device (VAD). Today, <3% of these patients are treated due to donor heart shortages and restrictive employment of VADs. VADs can cause severe complications, such as bleeding and strokes, and typically only support one side of the heart.
reBEAT is a revolutionary technology to mechanically support both sides of the heart, does not directly contact blood and can be easily implanted (~40 minutes). It presents virtually no contraindications for the patient population described. reBEAT offers high cost effectiveness at <50% of the cost of heart transplantations and VADs. AdjuCor expects revenues of 69M€ by 2027 with reBEAT.
ver más
Duración del proyecto: 26 meses
Fecha Inicio: 2022-10-26
Fecha Fin: 2024-12-31
Fecha Fin: 2024-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-10-26
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2022-ACCELERATOROPEN-01:
EIC Accelerator Open
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
ADJUCOR GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
